The co-author of the Fortune article, Robert Whitaker, edits a newsletter called CenterWatch. Most of what appeared about Zonagen is a rehash of an article from the Dec. 1 issue of his newsletter. Most of his conclusions are based on selective quotes, probably out of context and debatable interpretations of the chronology of events. I wonder if he has a position in Zonagen?
Regarding the side effects issues of racing hearts etc.; the article stated that all were at the 80mg dose, which will not be used. Only the 40 mg dose is being used in the open label trials and that is the only dosage that will be prescribed. No such side effects were reported with 40 mg.
When I first read the CenterWatch article, which was in late December, weeks after it was released, I was struck by how similar it was to what Asensio said. Now, the same author gets virtually the same words printed in Fortune. The deliberate manipulation continues by the same group of people.
I first heard about the Fortune article on Tuesday. If I knew, so did the market pros. I think that they are savvy enough to understand what is going on here. Any significant selling that was going to occur, IMHO, already has. We may see some small investors panic out tomorrow, but to the large holders, this is old news and any pullback may be used as a buying opportunity.
The last mention of Zonagen was in the next to the last paragraph. It reads: "Even Zonagen, with Schering-Plough behind it, has bounced back some - the stock traded recently at $22 a share, and its product isn't out of the race." |
